Zafgen, a biopharma company focused on obesity treatment, has filled out its Series C financing with an additional $3 million in debt financing, bringing the total round up to $36 million. The Series C leads from the initial $33 million round raised in July 2011 were Atlas Venture and Third Rock Ventures. Beloranib, Zafgen’s lead obesity therapy drug, works by targeting an enzyme called methione aminopeptidase 2 (MetAP2), which controls the production and utilization of fatty acids. Zafgen has racked up $66.3 million in equity financing to date.
